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scenarios from removing a PA on lubiprostone when cost per PA
>$15.34 or PA approval rate >74.83%, or expected increase in
prescriptions from lifting PA <19.99%. CONCLUSION: PA
program for lubiprostone offers no ﬁnancial savings to a health
plan based on current approval rates and annual utilization for
patients suffering from CC in the base case as well as in sensi-
tivity analyses.
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INFLAMMATORY BOWEL DISEASES (IBD) PATIENTS PROFILE:
FACTS EXTRACTED FROM A MULTICENTER RETROSPECTIVE
STUDY
Araujo G, Fonseca M
Axia.Bio Consulting, São Paulo, Brazil
OBJECTIVE: Access the Brazilian inﬂammatory bowel diseases
patients’ proﬁle METHODS: A retrospective database study was
performed in 23 IBD treatment centers in 14 Brazilian reference
cities. The centers collected data from the last 5 years about
personal data, disease important aspects (like race and smoking
habits), diagnosis and disease treatment. RESULTS: A total of
2529 medical records were analyzed. Crohnxs disease was the
most prevalent (49%) IBD. Sixty-ﬁve percent of the patients are
Caucasian and 9% are smokers. The median weight of the
patients are 62.5 kg and the median age 40.18% of the patients
came to the actual medical center with a previous IBD diagnostic
and 64% of this diagnosticated group came with a previous
treatment. CONCLUSION: This is the ﬁrst time that signiﬁcant
information about the Brazilian IBD patient proﬁle is evaluated.
Knowledge of the IBD could be a useful tool for supply policy
interventions. Combined with clinical data, this patient proﬁle
could contribute to the qualitative and quantitative evaluation of
disease management policy for this group pf illness.
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IMPORTANT FACTORSWHEN CONSIDERINGTREATMENT
FOR ULCERATIVE COLITIS
Waters H, Kelly J, Rahman MI
Centocor, Inc, Horsham, PA, USA
OBJECTIVE: To quantify preferences that ulcerative colitis (UC)
patients place on treatment attributes when making therapy
choices. METHODS: A telephonic survey of patients with
UC > 18 years old who requested information from the website
www.LivingWithUC.com from January to April 2006. Patients
were presented with nine factors that might impact a UC
patient’s decision-making process regarding whether to use a
biologic medication such as inﬂiximab. A discreet choice meth-
odology was employed using a complete block design, which
presented 9 factors being tested in 36 discreet pairs and patients
were asked to select the more important factor from each pair
presented. RESULTS: A total of 427 UC patients were contacted
to get 294 completed interviews. The median age was 50 years
and 204 (69.4%) were female. Of respondents currently on
medication, 71% indicated their symptoms were under control
and 75% of these respondents were experiencing 2 ﬂares per
year. One third (34%) of respondents classiﬁed their UC as being
moderate to severe. When asked about treatment options pre-
sented by their doctor, 42% had discussed surgery and 18% said
doctors indicated surgery was a cure for UC. Half (50%) recalled
their doctor presenting only one drug option, and of those pre-
sented with several options, 20% recall the physician emphasiz-
ing a particular drug. Respondents indicated healing the damage
of the intestinal lining (74%) and avoiding surgery (73%) were
important characteristics when deciding to use a product like
inﬂiximab to treat UC. Method of administration (23%) and cost
of co-pay (19%) were given least importance. CONCLUSION:
While doctors may focus on surgery as a cure for UC, patients in
this study state healing intestinal damage and avoiding surgery
would be their most important reasons to use a medication.
Doctors and patients may need to discuss a wider variety of
therapeutic options for treating UC before surgery is considered.
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OBJECTIVE: The Ontario Addiction Treatment Centres
(OATC) operates 26 clinics offering methadone maintenance
treatment (MMT) to clients with a dependence on opiates. Until
recently, MMT was a contraindication to antiviral therapy for
the treatment of Hepatitis C virus (HCV) infected patients. The
purpose of this study was 1) to describe a care model for treating
HCV infected MMT clients in a community-based setting, 2) to
describe clinical and demographic characteristics of these clients,
3) to assess rates of adherence to antiviral therapy, and 4) to
assess rates of sustained virological response (SVR). METHODS:
A review of patient medical records was employed. Clients con-
sidered for antiviral therapy at the OATC had achieved “func-
tional stability”, characterized by stable housing and a low
frequency of substance abuse, in addition to meeting clinical
criteria. Clients were followed by a hepatitis nurse, clinic physi-
cian or infectious disease specialist at the clinic where they
received methadone. Use of illicit substances was monitored
before, during and after antiviral therapy with regular urinalysis.
RESULTS: Between November 2002 and January 2006, 109
clients (75 with genotype 1/4 and 33 with genotype 2/3) received
at least one injection with pegylated interferon. The majority of
clients were single (60%), living in a permanent apartment or
house (94%), with a high frequency of self-reported psychiatric
disorders (68%). A large proportion had a criminal history
(71%) and many had been incarcerated (52%). Rates of adher-
ence to treatment of 57% and 70% were achieved for genotypes
1/4, and 2/3, respectively. Rates of SVR in an intention to treat
analysis were 51% for genotypes 1/4 and 64% for genotypes 2/3.
Six clients discontinued therapy due to on-going problems with
substance abuse. CONCLUSION: HCV antiviral therapy for
current or former substance abusers can be successful in the
context of specialized care for substance abuse.
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OBJECTIVE: To systematically review the effectiveness of pegy-
lated interferon (PEG), lamivudine (LAM), adefovir (ADF) and
entecavir (ENT) in treating CHB. METHODS: Pubmed, Embase,
Cochrane, and Econlit were searched for randomized controlled
trials assessing the efﬁcacy of the selected drugs for treating CHB
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published in the English language from dates of inception to
January 2007. Patients were considered to have CHB if they had
elevated ALT levels and active viral replication. Monotherapy,
combination and sequential therapies were included. Among
trials that met our inclusion criteria, we abstracted data describ-
ing normalization of ALT, HBV DNA, sustained biochemical
response, HBeAg seroconversion, histological improvement,
drop-outs and adverse events. Intention-to-treat data were com-
bined using a random-effects meta-analysis, with missing data
considered as treatment failures. Outcomes were expressed as
relative risks with 95% conﬁdence intervals. RESULTS: The
initial search yielded 2064 references, 127 were excluded due to
inadequate blinding, allocation concealment, randomization and
reporting of outcomes; 20 studies were included. Trials involved
5573 patients (4121 males, 1309 females), ranging in size from
200–814 patients. Mean age was 40.7. Eleven trials studied
HBeAg-positive patients, four trials studied HBeAg-negative
patients, and four trials studied both. Due to small numbers of
trials for comparison led to pooling of HBeAg-positive and
HBeAg-negative studies. No treatment was superior for all
outcome measures. Monotherapy was superior to placebo. Com-
parisons of single drugs favored treatment with ADF or ENT
over LAM or PEG. LAM was superior to PEG with better clinical
outcomes and fewer adverse events and patient dropouts. Com-
bination and sequential treatments were not superior, however
comparisons were limited by our one-year follow-up. CONCLU-
SION: Monotherapy with ADF or ENT are the most attractive
treatment options within the ﬁrst year of treatment. Further
research on combination and sequential therapies may provide
better options but presently insufﬁcient evidence exists to support
this approach.
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OBJECTIVE: The purpose of this study is to investigate treat-
ment options of osteomyelitis based on physician decisions
recorded in our dataset. METHODS: We want to ﬁnd the fre-
quency of a given input (code) for a variable, or more than one
variable in health care data. Using the Thomson MedStat
MarketScan data containing all patient claims for 40 million
observations, the primary diagnosis code is given for each
patient as well as ﬁfteen possible secondary diagnoses. We use
SAS Text Miner to demonstrate a simpliﬁed method to search
these ﬁfteen columns. We use ICD9 and CPT codes to ﬁnd
treatments for osteomyelitis. We also look for sequential treat-
ments for recurrence of osteomyelitis. After ﬁltering the data for
Osteomyelitis, there are 18,721 observations in inpatients that
contain 2661 patients, and 233,001 observations in outpatients
with 78,957 patients. RESULTS: The difference between the
number of observation and number of distinct patient IDs
shows that most patients have a sequence of procedures during
their treatment. After sorting the data by procedures, the most
frequent (20%) is “Dorsal and dorsolumbar fusion, posterior
technique”, second is “Excisional debridement of wound, infec-
tion, or burn” (15%), third “Amputation of toe” (9%), and in
forth place, “Revision of amputation stump” (7%). In the out-
patient data, the most frequent procedure is code 86.59
(Closure of skin and subcutaneous tissue of other sites) with
4021 records out of 8711 records. We found that about 8 % of
patients with osteomyelitis from inpatient data and about 0.3%
from outpatient data had amputation. CONCLUSION: While
amputation does not occur as often as debridement, we want to
examine the sequence of treatments to see whether amputation
follows a pattern of debridement.
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OBJECTIVE: To determine antimicrobial resistance proﬁles for
Enterococcus in 14 tertiary-level hospitals in Bogotá, Colombia.
METHODS: Time series analyses were performed, as well as
descriptive analyses of Enterococcus faecalis and Enterococcus
faecium in hospitals belonging to the Bogotá Bacterial Resistance
Control Group from January 1, 2001–January 1, 2007. We
identiﬁed the presence and species of enterococcus according to
anatomical site. RESULTS: During that period, a total of 5770
strains of Enterococci faecalis and 1259 of Enterococcus faecium
were analyzed. Enterococcus was found in >20% of isolates from
blood samples and abdominal ﬂuid in critical care units (SUCI)
and in >10% of samples from non-critical care services (SNUCI)
in tertiary-level hospitals in Bogotá. Ampicillin was active against
Enterococcus faecalis strains in Critical care units (SUCI) and
other services (SNUCI), but >50% of E.faecium strains in SNUCI
were resistant. Vancomycin-resistant strains occurred in >2%
of E.faecalis strains identiﬁed in SUCI and >8% in SNUCI.
The resistance trend in E.faecium to vancomycin in SNUCI was
towards the low in the six years studied. CONCLUSION: This
study conﬁrms the worldwide trend towards an increase in infec-
tions due to Enterococcus. The emerging pattern of antimicrobial
resistance among such isolates is alarming.
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OBJECTIVE: The danger of widespread and intense epidemics of
yellow fever (YF) in Africa has become very serious, requiring
urgent immunization response. Because it is not possible to vac-
cinate 100% of the adult population, the challenge is to prioritize
immunization of the population at highest risk. An original risk
assessment has been performed at the initiative of the World
Health Organization, using modeling to enable countries to
deﬁne populations currently at highest risk, which will be vacci-
nated in priority. METHODS: Five exposure risk factors have
been selected and collected at the district level in three African
countries: Burkina Faso, Togo, Mali. The ﬁve indicators are:
ecological risk zone, conﬁrmed YF cases since 1960, suspected
cases since 1960, number of years in which YF cases notiﬁed
since 1960, district close to another district that has notiﬁed cases
since 1960. A multi-criteria analysis based on multiple compo-
nent analysis (MCA) has constructed a composite exposure indi-
cator (CEi) from the ﬁve selected exposure risk factors. In
reducing by mathematical projections the number of dimensions,
MCA modeling synthesize complex data tables. RESULTS: For
each of the three target countries, three analyses have been done
for rural districts, urban districts and rural + urban districts.
Four risk clusters have been determined from the lowest risk to
the highest risks, allowing the construction of detailed YF risk
maps in Burkina-Faso, Togo and Mali. These “YF risk assess-
ment maps” present in four colors the four risk clusters at each
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